Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Ipsen will hold a conference call Thursday, 25 July 2018 at 2:30 p.m. (Paris time).

COSMIC-021 trial

Fulfilling our Bold Promise Through External Innovation

It’s time to talk about kidney cancer!